The FDA has finalized the terms of the consent decree regarding Genzyme’s Allston manufacturing plant, subject to approval by the U.S. District Court for the District of Massachusetts. Genzyme will pay an up-front disgorgement of past profits of $175 million. The company will continue to ship Cerezyme and Fabrazyme, which are manufactured, filled and finished in Allston, as well as Thyrogen, which is filled and finished at the plant. In the U.S., distribution of Thyrogen will be based on medical...